Moreover, insight into the molecular mechanisms underlying cancer, which EGFR and COX-2 interact with, has triggered interest in evaluating the combination of COX-2 and EGFR inhibitors in NSCLC treatment due to the fact that EGFR is activated via PGE2 [33,34,35,36,37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.